AELIX Therapeutics is a partner in the international Consortium of the MISTRAL project, funded within the framework of European Union’s Horizon 2020 programme with a Grant Agreement number 847943.
The MISTRAL project “Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications, antimicrobial drug resistance, and unresponsiveness to therapeutic HIV-1 vaccination” is exploring the gut microbiota in relation to HIV-1, seeking microbiome biomarkers to support development of interventions that mitigate infection and enhance response to vaccines and therapies. In addition, the creation of a publicly accessible database will aid in patient screening and stratification. A cloud-based tool will also facilitate microbiome interpretation for research and clinical purposes.
The budget of this project is € 9,99M.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847943